Collaborator: Policy Lab U.S
Link
Summary:
This is an open-label, ten-week, clinical trial of a proprietary high CBD/low THC sublingual solution (20mg/ml CBD and 0.58mg/ml THC) for the treatment of clinically significant anxiety and agitation in mild to moderate Alzheimer’s Disease.
Recruitment Status: Recruiting
Study Details:
Sponsor: Mclean Hospital
Collaborator: Spier Family Foundation
Information provided by (Responsible Party): Brent Forester, Mclean Hospital
Condition or Disease: Alzheimer Disease, Anxiety, Agitation, Psychomotor
Intervention/Treatment: Drug: High CBD/ Low THC sublingual solution
Phase: Phase 2
Study Type: Interventional (Clinical Trial)
Estimated Enrolment: 12 participants
Intervention Model: This is an open-label trial; all participants will receive the active drug.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open-Label Trial of a Cannabidiol Solution for the Treatment of Behavioral Symptoms in Older Adults With Alzheimer’s Dementia
Estimated Study Start Date: March 1, 2020
Estimated Primary Completion Date: November 1, 2021
Estimated Study Completion Date: November 1, 2021
